Itch in Atopic Dermatitis – What Is New?
Open Access
- 7 May 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
Abstract
Atopic dermatitis (AD) is among the most frequent inflammatory skin diseases in humans, affecting up to 20% of children and 10% of adults in higher income countries. Chronic pruritus is a disease-defining symptom of AD, representing the most burdensome symptom for patients. Severe chronic pruritus causes significant sleep disturbances and impaired quality of life, as well as increased anxiety, depression and suicidal behavior. Until recently, skin care, topical corticosteroids, and calcineurin-inhibitors were primarily used to treat mild to moderate AD, while phototherapy and immunosuppressive agents such as corticosteroids, cyclosporine, and methotrexate were used to treat patients with moderate to severe AD. The potential short- and long-term adverse events associated with these treatments or their insufficient therapeutic efficacy limited their use in controlling pruritus and eczema in AD patients over longer periods of time. As our understanding of AD pathophysiology has improved and new systemic and topical treatments have appeared on the market, targeting specific cytokines, receptors, or their intracellular signaling, a new era in atopic dermatitis and pruritus therapy has begun. This review highlights new developments in AD treatment, placing a specific focus on their anti-pruritic effects.This publication has 88 references indexed in Scilit:
- Proteinase-activated receptors (PARs) – focus on receptor-receptor-interactions and their physiological and pathophysiological impactCell Communication and Signaling, 2013
- Chronic PruritusThe New England Journal of Medicine, 2013
- Systemic Kappa Opioid Receptor Agonists in the Treatment of Chronic Pruritus: A Literature ReviewActa Dermato-Venereologica, 2012
- TH2 cytokines increase kallikrein 7 expression and function in patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 2012
- Calcitonin gene-related peptide modulates interleukin-13 in circulating cutaneous lymphocyte-associated antigen-positive T cells in patients with atopic dermatitisBritish Journal of Dermatology, 2009
- Kallikrein 5 induces atopic dermatitis–like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndromeThe Journal of Experimental Medicine, 2009
- Decreased production of semaphorin 3A in the lesional skin of atopic dermatitisBritish Journal of Dermatology, 2008
- Cytokine modulation of atopic dermatitis filaggrin skin expressionJournal of Allergy and Clinical Immunology, 2007
- Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritusJournal of Allergy and Clinical Immunology, 2007
- IL-31: A new link between T cells and pruritus in atopic skin inflammationJournal of Allergy and Clinical Immunology, 2006